Valuation : Ipsen S.A.

Market Cap 12.88B 14.95B 12.2B 11.05B 20.74B 1,428B 20.84B 145B 55.7B 727B 56.14B 54.91B 2,296B P/E 2026 *
13.1x
P/E 2027 * 13.4x
Enterprise Value 11.64B 13.51B 11.02B 9.99B 18.75B 1,291B 18.84B 131B 50.35B 657B 50.75B 49.64B 2,075B EV / Sales 2026 *
2.56x
EV / Sales 2027 * 2.28x
Free-Float
40.65%
Yield 2026 *
0.98%
Yield 2027 * 0.98%
1 day-0.82%
1 week-3.95%
Current month-3.01%
1 month+2.33%
3 months+0.32%
6 months+2.60%
Current year+31.91%
1 week 156.4
Extreme 156.4
165.4
1 month 153.4
Extreme 153.4
170.5
Current year 116.4
Extreme 116.4
173.1
1 year 110.6
Extreme 110.6
173.1
3 years 88.3
Extreme 88.3
173.1
5 years 77.62
Extreme 77.62
173.1
10 years 66.65
Extreme 66.65
173.1
Manager TitleAgeSince
Chief Executive Officer 59 2020-06-30
Chief Executive Officer 57 2019-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 2005-08-29
Chairman 68 2010-11-21
Director/Board Member 69 2012-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-3.95% - - 14.95B
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average -0.74%-5.76%+22.08%+40.35% 389.42B
Weighted average by Cap. -0.51%-4.42%+30.96%+54.95%

Financials

2026 *2027 *
Net sales 4.54B 5.27B 4.3B 3.9B 7.32B 504B 7.35B 51.09B 19.65B 256B 19.8B 19.37B 810B 4.64B 5.38B 4.39B 3.98B 7.47B 514B 7.5B 52.15B 20.05B 262B 20.21B 19.77B 827B
Net income 1.01B 1.17B 957M 867M 1.63B 112B 1.64B 11.37B 4.37B 57.02B 4.41B 4.31B 180B 985M 1.14B 933M 846M 1.59B 109B 1.59B 11.08B 4.26B 55.59B 4.3B 4.2B 176B
Net Debt -1.24B -1.44B -1.17B -1.06B -1.99B -137B -2B -13.92B -5.35B -69.84B -5.4B -5.28B -221B -2.3B -2.67B -2.18B -1.97B -3.7B -255B -3.72B -25.86B -9.94B -130B -10.02B -9.8B -410B
Logo Ipsen S.A.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
26-09-11 €157.80 -0.06%
26-09-10 €157.90 -0.82%
26-09-09 €159.20 +0.89%
26-09-08 €157.80 -4.59%
26-09-07 €165.40 +0.61%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
157.10EUR
Average target price
166.07EUR
Spread / Average Target
+5.71%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!